{
    "hands_on_practices": [
        {
            "introduction": "Bulk-forming laxatives like psyllium are mainstays in treating constipation, acting by increasing the water content and mass of stool. To truly understand their effect, we can move beyond qualitative descriptions and build a quantitative model. This practice challenges you to apply the principle of mass conservation to calculate the expected increase in stool weight, linking the fiber's properties—such as its fermentability and water-holding capacity—directly to its clinical outcome. ",
            "id": "4960318",
            "problem": "A patient with chronic functional constipation is prescribed daily psyllium husk, a soluble fiber laxative, to increase stool bulk and normalize colonic transit. Use the following fundamental bases: (i) conservation of mass for ingested fiber, where the fraction that is microbially fermented in the colon is converted into products that are absorbed and therefore do not add to stool mass; and (ii) water-binding capacity of residual fiber, where water retained by the fiber matrix contributes to stool weight until defecation. The patient ingests $10$ g per day of psyllium. In the colon, a fraction $f = 0.60$ of the fiber is fermented and lost from the stool mass, and the remaining fraction $1 - f$ passes unabsorbed into feces. For each gram of residual fiber, the water-holding capacity is $4$ g water per gram fiber, and the associated bound water is not reabsorbed prior to defecation. Neglect endogenous secretions, any osmotic effects beyond the stated water-binding, and any changes in colonic transit time that would alter water reabsorption independent of fiber binding.\n\nBased on these principles, compute the expected increase in daily stool weight due solely to the ingested psyllium and the water it binds. Express your answer in grams (g). No rounding is required; report the exact value.",
            "solution": "The problem requires the calculation of the increase in daily stool weight due to the ingestion of psyllium, based on a model of fiber fermentation and water binding. The total increase in stool weight, denoted as $\\Delta W_{\\text{stool}}$, is the sum of two components: the mass of the unfermented (residual) fiber that enters the stool, and the mass of the water that this residual fiber binds and retains until defecation.\n\nWe are provided with the following information:\n- The daily mass of ingested psyllium fiber, $M_{\\text{ingested}} = 10$ g.\n- The fraction of the ingested fiber that is microbially fermented in the colon, $f = 0.60$. This portion is converted into products that are absorbed and thus do not contribute to the final stool mass.\n- The water-holding capacity of the residual fiber, $C_w = 4$ g of water per gram of fiber.\n\nThe first step is to determine the mass of the psyllium fiber that is not fermented and therefore becomes a solid component of the stool. This is the residual fiber mass, $M_{\\text{residual}}$. It is calculated by multiplying the total ingested mass by the fraction that remains unfermented, which is $(1 - f)$.\n$$M_{\\text{residual}} = M_{\\text{ingested}} \\times (1 - f)$$\nSubstituting the given numerical values:\n$$M_{\\text{residual}} = 10 \\text{ g} \\times (1 - 0.60) = 10 \\text{ g} \\times 0.40 = 4 \\text{ g}$$\nTherefore, $4$ g of solid fiber mass is added to the daily stool.\n\nThe second step is to calculate the mass of water, $M_{\\text{water}}$, that is bound by this residual fiber. The problem states that this bound water is not reabsorbed and is excreted with the stool. The mass of this water is determined by the mass of the residual fiber and its specific water-holding capacity, $C_w$.\n$$M_{\\text{water}} = M_{\\text{residual}} \\times C_w$$\nUsing the value of $M_{\\text{residual}}$ we just calculated:\n$$M_{\\text{water}} = 4 \\text{ g} \\times \\left( \\frac{4 \\text{ g water}}{1 \\text{ g fiber}} \\right) = 16 \\text{ g}$$\nThis means that an additional $16$ g of water is retained in the stool.\n\nFinally, the total increase in daily stool weight, $\\Delta W_{\\text{stool}}$, is the sum of the mass of the residual fiber and the mass of the water it binds.\n$$\\Delta W_{\\text{stool}} = M_{\\text{residual}} + M_{\\text{water}}$$\nSumming the calculated masses:\n$$\\Delta W_{\\text{stool}} = 4 \\text{ g} + 16 \\text{ g} = 20 \\text{ g}$$\nBased on the provided model, the expected increase in daily stool weight is $20$ g.",
            "answer": "$$\\boxed{20}$$"
        },
        {
            "introduction": "Loperamide is an opioid receptor agonist, yet it's used as an over-the-counter antidiarrheal with minimal central nervous system side effects. This apparent paradox is explained by key pharmacokinetic principles that limit its brain exposure. This exercise provides a hands-on opportunity to quantify how extensive first-pass metabolism and active efflux by P-glycoprotein at the blood-brain barrier work in concert to maintain loperamide's peripheral action. ",
            "id": "4960281",
            "problem": "A patient takes loperamide orally for acute diarrhea. Loperamide produces minimal central nervous system (CNS) effects because (i) P-glycoprotein (P-gp) at the blood–brain barrier (BBB) effluxes loperamide from brain endothelial cells back to blood, and (ii) extensive first-pass metabolism reduces systemic exposure. Starting from fundamental pharmacokinetic bases, construct a quantitative mechanistic account linking these processes to the brain/plasma concentration ratio, then compute that ratio under baseline conditions and after potent P-gp inhibition.\n\nAssume the following scientifically plausible scenario in which loperamide exhibits linear kinetics and the brain interstitial fluid is well mixed:\n\n- Oral input is at a constant rate $R_{\\text{oral}} = 8\\,\\text{mg}\\,\\text{h}^{-1}$.\n- The fraction absorbed from the gut is $f_{\\text{abs}} = 0.95$.\n- The hepatic extraction ratio is $E_{h} = 0.85$.\n- Systemic clearance is $CL_{\\text{sys}} = 40\\,\\text{L}\\,\\text{h}^{-1}$.\n- The fraction unbound in plasma is $f_{u,\\text{plasma}} = 0.02$.\n\nAt the BBB, free loperamide crosses via passive diffusion into brain with an unidirectional influx clearance $CL_{\\text{in}} = 0.05\\,\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$, and leaves the brain by two parallel routes: passive efflux $CL_{\\text{passive}} = 0.10\\,\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$ and P-gp–mediated efflux $CL_{\\text{pgp,base}} = 1.40\\,\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$. A potent P-gp inhibitor reduces P-gp–mediated efflux clearance by $80\\%$ relative to baseline. Assume the brain/plasma ratio refers to the ratio of free interstitial fluid concentration in brain to free concentration in plasma at steady state, and that P-gp efflux is effectively linear in the range of concentrations achieved.\n\nTasks:\n\n1. Using fundamental definitions of oral bioavailability and clearance, determine the steady-state free plasma concentration $C_{\\text{p,free}}$ resulting from the oral input. Treat bioavailability $F$ as the product of absorption and the fraction escaping hepatic extraction. Express $C_{\\text{p,free}}$ in $\\text{mg}\\,\\text{L}^{-1}$ and round to four significant figures.\n\n2. Starting from flux conservation at steady state and the clearance concept for parallel efflux pathways, derive an expression for the steady-state brain/plasma concentration ratio $K_{p,\\text{brain}}$ in terms of $CL_{\\text{in}}$, $CL_{\\text{passive}}$, and $CL_{\\text{pgp}}$.\n\n3. Compute $K_{p,\\text{brain}}$ under baseline conditions (using $CL_{\\text{pgp,base}}$) and after P-gp inhibition (using the inhibited $CL_{\\text{pgp}}$). Treat the ratio as dimensionless and express both values as decimals. Round your final ratios to four significant figures. Report the two ratios, in the order (baseline, inhibited), as your final answer in a two-component row vector. The final answer must contain no units.",
            "solution": "The solution is organized according to the three tasks specified in the problem statement.\n\n**Task 1: Determination of the steady-state free plasma concentration, $C_{\\text{p,free}}$**\n\nFirst, we calculate the oral bioavailability, $F$. This is the fraction of the orally administered dose that reaches the systemic circulation. It is given as the product of the fraction absorbed from the gut, $f_{\\text{abs}}$, and the fraction of the absorbed drug that escapes first-pass metabolism in the liver, $(1 - E_{h})$.\n$$F = f_{\\text{abs}} (1 - E_{h})$$\nSubstituting the given values:\n$$F = 0.95 \\times (1 - 0.85) = 0.95 \\times 0.15 = 0.1425$$\nThe effective rate of drug entry into the systemic circulation, $R_{\\text{in,sys}}$, is the oral input rate $R_{\\text{oral}}$ multiplied by the bioavailability $F$.\n$$R_{\\text{in,sys}} = R_{\\text{oral}} \\times F$$\n$$R_{\\text{in,sys}} = (8\\,\\text{mg}\\,\\text{h}^{-1}) \\times 0.1425 = 1.14\\,\\text{mg}\\,\\text{h}^{-1}$$\nAt steady state, the rate of drug entry into the systemic circulation equals the rate of drug elimination from the body. The rate of elimination is the product of the total systemic clearance, $CL_{\\text{sys}}$, and the total steady-state plasma concentration, $C_{\\text{p,total}}$.\n$$\\text{Rate of entry} = \\text{Rate of elimination}$$\n$$R_{\\text{in,sys}} = CL_{\\text{sys}} \\times C_{\\text{p,total}}$$\nWe can solve for $C_{\\text{p,total}}$:\n$$C_{\\text{p,total}} = \\frac{R_{\\text{in,sys}}}{CL_{\\text{sys}}} = \\frac{1.14\\,\\text{mg}\\,\\text{h}^{-1}}{40\\,\\text{L}\\,\\text{h}^{-1}} = 0.0285\\,\\text{mg}\\,\\text{L}^{-1}$$\nThe problem asks for the *free* plasma concentration, $C_{\\text{p,free}}$. This is related to the total concentration by the fraction unbound in plasma, $f_{u,\\text{plasma}}$.\n$$C_{\\text{p,free}} = C_{\\text{p,total}} \\times f_{u,\\text{plasma}}$$\n$$C_{\\text{p,free}} = (0.0285\\,\\text{mg}\\,\\text{L}^{-1}) \\times 0.02 = 0.00057\\,\\text{mg}\\,\\text{L}^{-1}$$\nRounding to four significant figures as required:\n$$C_{\\text{p,free}} = 0.0005700\\,\\text{mg}\\,\\text{L}^{-1}$$\n\n**Task 2: Derivation of the steady-state brain/plasma concentration ratio, $K_{p,\\text{brain}}$**\n\nThe ratio $K_{p,\\text{brain}}$ is defined as the ratio of the free drug concentration in the brain interstitial fluid, $C_{\\text{brain,free}}$, to the free drug concentration in plasma, $C_{\\text{p,free}}$, at steady state.\n$$K_{p,\\text{brain}} = \\frac{C_{\\text{brain,free}}}{C_{\\text{p,free}}}$$\nAt steady state in the brain compartment, the rate of drug influx must equal the rate of drug efflux. The rates are expressed per unit mass of brain tissue.\n\nThe rate of influx, $v_{\\text{in}}$, is driven by the free plasma concentration and is determined by the influx clearance, $CL_{\\text{in}}$.\n$$v_{\\text{in}} = CL_{\\text{in}} \\times C_{\\text{p,free}}$$\nThe rate of efflux, $v_{\\text{out}}$, is driven by the free brain concentration and occurs via two parallel pathways: passive diffusion and P-gp-mediated transport. The total efflux clearance, $CL_{\\text{out}}$, is the sum of the clearances for these parallel pathways.\n$$CL_{\\text{out}} = CL_{\\text{passive}} + CL_{\\text{pgp}}$$\nTherefore, the rate of efflux is:\n$$v_{\\text{out}} = CL_{\\text{out}} \\times C_{\\text{brain,free}} = (CL_{\\text{passive}} + CL_{\\text{pgp}}) \\times C_{\\text{brain,free}}$$\nEquating the influx and efflux rates at steady state:\n$$v_{\\text{in}} = v_{\\text{out}}$$\n$$CL_{\\text{in}} \\times C_{\\text{p,free}} = (CL_{\\text{passive}} + CL_{\\text{pgp}}) \\times C_{\\text{brain,free}}$$\nRearranging this equation to solve for the ratio $K_{p,\\text{brain}} = \\frac{C_{\\text{brain,free}}}{C_{\\text{p,free}}}$ gives the desired expression:\n$$K_{p,\\text{brain}} = \\frac{CL_{\\text{in}}}{CL_{\\text{passive}} + CL_{\\text{pgp}}}$$\nThis expression relates the steady-state free brain-to-plasma concentration ratio to the underlying BBB transport clearances.\n\n**Task 3: Computation of $K_{p,\\text{brain}}$ under baseline and inhibited conditions**\n\nWe use the derived formula and the provided clearance values. The clearance units are all $\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$, so they will cancel, yielding a dimensionless ratio.\n\n*   **Baseline condition:**\n    In this case, $CL_{\\text{pgp}} = CL_{\\text{pgp,base}} = 1.40\\,\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$.\n    $$K_{p,\\text{brain,base}} = \\frac{CL_{\\text{in}}}{CL_{\\text{passive}} + CL_{\\text{pgp,base}}}$$\n    $$K_{p,\\text{brain,base}} = \\frac{0.05}{0.10 + 1.40} = \\frac{0.05}{1.50} = 0.033333...$$\n    Rounding to four significant figures, we get:\n    $$K_{p,\\text{brain,base}} \\approx 0.03333$$\n\n*   **P-gp inhibited condition:**\n    The P-gp inhibitor reduces the P-gp-mediated efflux clearance by $80\\%$. The new clearance, $CL_{\\text{pgp,inhib}}$, is $20\\%$ of the baseline value.\n    $$CL_{\\text{pgp,inhib}} = CL_{\\text{pgp,base}} \\times (1 - 0.80) = 1.40 \\times 0.20 = 0.28\\,\\text{mL}\\,\\text{min}^{-1}\\,\\text{g}^{-1}$$\n    Now, we compute the new ratio, $K_{p,\\text{brain,inhib}}$:\n    $$K_{p,\\text{brain,inhib}} = \\frac{CL_{\\text{in}}}{CL_{\\text{passive}} + CL_{\\text{pgp,inhib}}}$$\n    $$K_{p,\\text{brain,inhib}} = \\frac{0.05}{0.10 + 0.28} = \\frac{0.05}{0.38} = 0.1315789...$$\n    Rounding to four significant figures, we get:\n    $$K_{p,\\text{brain,inhib}} \\approx 0.1316$$\n\nThe two ratios are $0.03333$ (baseline) and $0.1316$ (inhibited). These are to be reported as a two-component row vector.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.03333  0.1316\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Effective pharmacotherapy extends beyond understanding mechanisms to making informed clinical decisions for individual patients. This practice places you in the role of a clinician choosing between two osmotic laxatives, magnesium hydroxide and polyethylene glycol ($PEG$), for an elderly patient with chronic kidney disease. Using data from a hypothetical clinical trial, you will apply fundamental epidemiological tools like the Number Needed to Treat ($NNT$) and Number Needed to Harm ($NNH$) to perform a rigorous risk-benefit analysis. ",
            "id": "4960325",
            "problem": "An $82$-year-old woman with chronic idiopathic constipation and stage $3$ chronic kidney disease (estimated creatinine clearance $45$ $\\mathrm{mL/min}$) presents for treatment selection. She is deciding between magnesium hydroxide and Polyethylene Glycol (PEG). Osmotic laxatives act by increasing luminal water to soften stool and promote peristalsis; magnesium salts can be systemically absorbed and, with reduced renal clearance, elevate serum magnesium, while PEG is minimally absorbed and has a low risk of electrolyte disturbances. A randomized, double-blind trial of elderly patients compared once-daily magnesium hydroxide ($30$ $\\mathrm{mL}$) versus PEG ($17$ $\\mathrm{g}$) for $2$ weeks. The predefined treatment response was achieving $\\geq 3$ spontaneous bowel movements per week by week $2$. In the elderly subgroup, the response rate was $55\\%$ with magnesium hydroxide and $68\\%$ with PEG. Clinically significant electrolyte disturbance requiring intervention occurred in $6\\%$ with magnesium hydroxide and $1\\%$ with PEG overall; in stage $3$ chronic kidney disease, the electrolyte disturbance risk with magnesium hydroxide was observed to be approximately doubled relative to the overall cohort, while the PEG disturbance risk remained approximately the same. Median time to first bowel movement was $18$ hours with magnesium hydroxide and $24$ hours with PEG; stool consistency improvements by Bristol stool scale were similar across arms.\n\nUsing the fundamental definitions of absolute risk, risk difference, and the benefit–harm framework, and restricting attention to the patient’s stage $3$ chronic kidney disease subgroup for safety estimates, which option best characterizes the comparative risk–benefit between PEG and magnesium hydroxide for this patient, including the approximate frequency metrics for benefit and harm?\n\nA. Selecting PEG over magnesium hydroxide yields an absolute efficacy advantage of approximately $13\\%$ (Number Needed to Treat $\\approx 8$) and avoids an absolute electrolyte disturbance risk of approximately $11\\%$ (corresponding Number Needed to Harm for magnesium hydroxide versus PEG $\\approx 9$); therefore PEG is favored overall despite a slightly slower onset.\n\nB. Magnesium hydroxide is preferred because its faster onset ($18$ versus $24$ hours) confers superior overall benefit; PEG’s efficacy advantage is small (Number Needed to Treat $\\approx 20$) and magnesium hydroxide has fewer electrolyte disturbances than PEG (Number Needed to Harm $50$).\n\nC. Both agents are effectively equivalent; the absolute efficacy difference is $5\\%$ and electrolyte disturbance rates differ by $\\leq 2\\%$, so selection should be driven primarily by acquisition cost rather than clinical differences.\n\nD. PEG is superior in efficacy (Number Needed to Treat $\\approx 8$), but electrolyte disturbances are negligible and similar across agents even in chronic kidney disease (Number Needed to Harm $100$), making either agent acceptable; the faster onset of magnesium hydroxide can guide choice.",
            "solution": "### Derivation of Solution\n\nThe task is to perform a comparative risk-benefit analysis for the specified patient, focusing on efficacy and safety, and using the metrics of absolute risk difference, NNT, and NNH.\n\n**1. Efficacy Analysis (Benefit)**\n\nThe benefit is achieving the primary endpoint of $\\geq 3$ spontaneous bowel movements per week. We compare the response rates of PEG and magnesium hydroxide.\n\n*   Response rate with PEG, $R_{PEG} = 68\\% = 0.68$.\n*   Response rate with magnesium hydroxide, $R_{Mg} = 55\\% = 0.55$.\n\nThe absolute efficacy advantage of PEG over magnesium hydroxide is the absolute risk reduction (ARR), also known as the risk difference (RD) for a positive outcome.\n\n$$ARR = R_{PEG} - R_{Mg} = 0.68 - 0.55 = 0.13$$\nThis corresponds to an absolute efficacy advantage of $13\\%$.\n\nThe Number Needed to Treat (NNT) is the number of patients who need to be treated with the experimental therapy (PEG) instead of the control therapy (magnesium hydroxide) for one additional patient to experience the beneficial outcome. It is the reciprocal of the ARR.\n\n$$NNT = \\frac{1}{ARR} = \\frac{1}{0.13} \\approx 7.69$$\nRounding to the nearest integer, the $NNT \\approx 8$.\n\n**2. Safety Analysis (Harm)**\n\nThe harm is a clinically significant electrolyte disturbance. The problem specifies using the safety estimates for the stage $3$ CKD subgroup.\n\n*   Harm rate for magnesium hydroxide in the overall cohort, $H_{Mg, overall} = 6\\% = 0.06$.\n*   For the stage $3$ CKD subgroup, this risk is \"approximately doubled\":\n    $$H_{Mg, CKD3} \\approx 2 \\times H_{Mg, overall} = 2 \\times 0.06 = 0.12$$\n    So, the harm rate for magnesium hydroxide in this patient is approximately $12\\%$.\n\n*   Harm rate for PEG in the overall cohort, $H_{PEG, overall} = 1\\% = 0.01$.\n*   For the stage $3$ CKD subgroup, this risk \"remained approximately the same\":\n    $$H_{PEG, CKD3} \\approx H_{PEG, overall} = 0.01$$\n    So, the harm rate for PEG in this patient is approximately $1\\%$.\n\nThe absolute risk increase (ARI) of harm with magnesium hydroxide compared to PEG is the difference in their harm rates. This is the absolute risk that is avoided by choosing PEG.\n\n$$ARI = H_{Mg, CKD3} - H_{PEG, CKD3} \\approx 0.12 - 0.01 = 0.11$$\nThis corresponds to an absolute harm risk of $11\\%$ that is avoided by using PEG.\n\nThe Number Needed to Harm (NNH) is the number of patients who, if they received the experimental therapy (magnesium hydroxide) instead of the control (PEG), would result in one additional patient experiencing the adverse event. It is the reciprocal of the ARI.\n\n$$NNH = \\frac{1}{ARI} = \\frac{1}{0.11} \\approx 9.09$$\nRounding to the nearest integer, the $NNH \\approx 9$.\n\n**3. Risk-Benefit Synthesis**\n\n*   **Benefit:** PEG provides a clinically meaningful efficacy advantage over magnesium hydroxide, with an absolute benefit of $13\\%$ and an NNT of approximately $8$.\n*   **Harm:** Magnesium hydroxide poses a substantially higher risk of electrolyte disturbances in this patient with stage $3$ CKD, with an absolute risk increase of $11\\%$ and an NNH of approximately $9$. An NNH of $9$ indicates a significant potential for harm.\n*   **Conclusion:** The analysis clearly favors PEG. It is both more effective ($NNT \\approx 8$) and significantly safer ($NNH \\approx 9$) in this patient population. The minor advantage of a faster onset for magnesium hydroxide ($18$ hours vs. $24$ hours) is of little clinical significance when weighed against the superior efficacy and, more importantly, the substantial safety advantage of PEG.\n\n### Option-by-Option Analysis\n\n*   **A. Selecting PEG over magnesium hydroxide yields an absolute efficacy advantage of approximately $13\\%$ (Number Needed to Treat $\\approx 8$) and avoids an absolute electrolyte disturbance risk of approximately $11\\%$ (corresponding Number Needed to Harm for magnesium hydroxide versus PEG $\\approx 9$); therefore PEG is favored overall despite a slightly slower onset.**\n    *   This option correctly states the absolute efficacy advantage is $13\\%$ ($0.68 - 0.55 = 0.13$).\n    *   This option correctly calculates the NNT as $\\approx 8$ ($1/0.13 \\approx 7.69$).\n    *   This option correctly calculates the avoided absolute electrolyte risk as $11\\%$ ($0.12 - 0.01 = 0.11$).\n    *   This option correctly calculates the NNH as $\\approx 9$ ($1/0.11 \\approx 9.09$).\n    *   The concluding statement that PEG is favored is consistent with this robust risk-benefit analysis.\n    *   **Verdict: Correct.**\n\n*   **B. Magnesium hydroxide is preferred because its faster onset ($18$ versus $24$ hours) confers superior overall benefit; PEG’s efficacy advantage is small (Number Needed to Treat $\\approx 20$) and magnesium hydroxide has fewer electrolyte disturbances than PEG (Number Needed to Harm $50$).**\n    *   The claim that magnesium hydroxide is preferred is a poor clinical conclusion.\n    *   The calculated NNT of $\\approx 20$ is incorrect. Our calculation is $NNT \\approx 8$.\n    *   The statement that magnesium hydroxide has fewer electrolyte disturbances is factually incorrect based on the problem data ($12\\%$ vs. $1\\%$).\n    *   The NNH of $50$ is incorrect. Our calculation is $NNH \\approx 9$.\n    *   **Verdict: Incorrect.**\n\n*   **C. Both agents are effectively equivalent; the absolute efficacy difference is $5\\%$ and electrolyte disturbance rates differ by $\\leq 2\\%$, so selection should be driven primarily by acquisition cost rather than clinical differences.**\n    *   The claim that the absolute efficacy difference is $5\\%$ is false; it is $13\\%$.\n    *   The claim that electrolyte disturbance rates differ by $\\leq 2\\%$ is false; the difference is $11\\%$.\n    *   The conclusion that the agents are equivalent is based on these false premises.\n    *   **Verdict: Incorrect.**\n\n*   **D. PEG is superior in efficacy (Number Needed to Treat $\\approx 8$), but electrolyte disturbances are negligible and similar across agents even in chronic kidney disease (Number Needed to Harm $100$), making either agent acceptable; the faster onset of magnesium hydroxide can guide choice.**\n    *   This option correctly states the NNT as $\\approx 8$.\n    *   However, it incorrectly characterizes the electrolyte disturbance risk as \"negligible\" and gives an NNH of $100$. This is grossly inaccurate; the risk difference is significant ($11\\%$) and the NNH is low ($\\approx 9$), indicating substantial harm.\n    *   The conclusion that either agent is acceptable is therefore medically unsound.\n    *   **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}